LILRB2 and cancer: In agreement with Knaack et al. [21], who performed a pan-cancer modular regulatory network analysis of six human cancers and concluded that they share a common regulatory network, we found that the validated DEGs were involved in the cell cycle (CDC20, PLK1, GADD45A, and CDC45), immune response (TCL1A, GPR65, LILRB2, LY86, CD72, and NT5E), chromatin remodeling (HIST1H3G), and vesicle trafficking (STON2 and CNN3) and were either part of or encoded for important kinases upstream and downstream major signaling pathways for B cell differentiation (RUNX2, PIK3CG, IL7R, and HCK).